Imunon, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Imunon is a clinical-stage biotechnology company developing non-viral DNA therapies and vaccines; it reported no material product revenue and remains dependent on financing to fund development.
Financial performance and position
| Metric | Q3 2023 / September 30, 2023 | Comparable period / December 31, 2022 |
|---|---|---|
| Revenue | $0 | Q3 2022: $125,000 |
| Operating expenses | $3.90 million | Q3 2022: $6.30 million |
| Net loss | $3.48 million; $0.37 per share | Q3 2022: $6.15 million; $0.87 per share |
| Nine-month net loss | $14.63 million; $1.64 per share | Nine months 2022: $22.67 million; $3.42 per share |
| Cash, cash equivalents, short-term investments and accrued interest | $19.47 million | Year-end 2022: approximately $32.88 million, including restricted cash |
| Current assets / current liabilities | $21.73 million / $5.32 million | Year-end 2022: $36.78 million / $10.04 million |
| Debt | No notes payable outstanding | $6.04 million net notes payable at year-end 2022 |
For the first nine months, operating cash use was $15.25 million; investing activities provided $14.31 million, largely reflecting investment maturities and sales; financing activities used $3.67 million. The company reported $16.41 million of working capital. Profit margins are not meaningful given the absence of revenue and continuing operating losses.
Material changes versus prior periods
- Operating expenses fell 38% in Q3 and 18% for the nine-month period year over year. Lower general and administrative spending was a key contributor; R&D also declined overall, while spending on the PlaCCine vaccine platform and manufacturing/CMC increased.
- Licensing revenue ceased after the Hisun agreement’s deferred revenue was fully recognized by year-end 2022.
- Nine-month net loss improved from 2022, in part because the prior-year period included approximately $4.55 million of expense related to issuance and redemption of convertible preferred stock. 2023 included a $329,000 loss on early repayment of the SVB loan.
- The company repaid its SVB facility on April 21, 2023, paying $6.42 million, including principal, early termination and end-of-term charges. Repayment also released the related $6.0 million restricted-cash requirement.
- Common shares outstanding rose from 7.44 million at December 31, 2022 to 9.37 million at September 30, 2023. The company sold 1.88 million shares through its at-the-market facility in the first nine months for approximately $2.75 million net.
Outlook, management commentary and risks
- Management stated that approximately $19.5 million in cash, cash equivalents, short-term investments and accrued interest, together with approximately $1.8 million of planned New Jersey NOL sales, was expected to fund operations for 12 months from issuance of the financial statements. Planned NOL proceeds include $1.5 million in 2023 and $0.3 million in 2024.
- Management expects operating losses to continue and says additional capital will be needed to advance research, trials and manufacturing. It may seek equity or debt financing, collaborations, licensing arrangements, grants or further NOL sales; equity financing could dilute shareholders. Insufficient funding could require delaying, reducing or ending programs.
- IMNN-001 is in Phase 2 development for advanced ovarian cancer. September 2023 interim OVATION 2 data showed a reported approximately 33% delay in disease progression versus control and approximately nine months of preliminary OS improvement; management described these results as trends. Topline results were expected in mid-2024. Reported PARP-inhibitor subgroup results were preliminary and not pre-specified.
- A Phase 1/2 study of IMNN-001 with bevacizumab began treating its first patient in October 2023. The company expected to submit an IND for its IMNN-101 seasonal COVID-19 booster in Q1 2024 and anticipated Phase 1/2 enrollment in Q2 2024. These are forward-looking timelines, not reported outcomes.
- Key risks include clinical and regulatory uncertainty, trial enrollment and execution, competition, intellectual-property matters, and the ability to raise capital. The company reported no material change to the risk factors in its 2022 Form 10-K.
- The Spar securities class action was dismissed without prejudice in September 2023 after the plaintiff did not amend the complaint by the deadline. A separate derivative shareholder action remained stayed; the company said potential loss could not be estimated.
Most important facts for investors to verify
- Whether cash burn, financing activity and NOL-sale proceeds support operations beyond management’s stated 12-month funding horizon.
- Final OVATION 2 efficacy and safety results, including whether interim PFS and OS trends are confirmed in the full analysis.
- Actual timing and regulatory progress for IMNN-101 and the IMNN-001/bevacizumab trial.
- Further share issuance, dilution, and the remaining capacity or terms of the at-the-market offering facility.
- Developments in the stayed derivative lawsuit and any change in the company’s assessment of potential losses.